Recapitulating and reversing human brain ribosomopathy defects via the maladaptive integrated stress response

Wei Zhang,Minjie Zhang,Li Ma,Supawadee Jariyasakulroj,Qing Chang,Ziying Lin,Zhipeng Lu,Jian-Fu Chen

DOI: https://doi.org/10.1126/sciadv.adk1034

IF: 13.6

2024-02-03

Science Advances

Abstract:Animal or human models recapitulating brain ribosomopathies are incomplete, hampering development of urgently needed therapies. Here, we generated genetic mouse and human cerebral organoid models of brain ribosomopathies, caused by mutations in small nucleolar RNA (snoRNA) SNORD118 . Both models exhibited protein synthesis loss, proteotoxic stress, and p53 activation and led to decreased proliferation and increased death of neural progenitor cells (NPCs), resulting in brain growth retardation, recapitulating features in human patients. Loss of SNORD118 function resulted in an aberrant upregulation of p-eIF2α, the mediator of integrated stress response (ISR). Using human iPSC cell–based screen, we identified small-molecule 2BAct, an ISR inhibitor, which potently reverses mutant NPC defects. Targeting ISR by 2BAct mitigated ribosomopathy defects in both cerebral organoid and mouse models. Thus, our SNORD118 mutant organoid and mice recapitulate human brain ribosomopathies and cross-validate maladaptive ISR as a key disease-driving mechanism, pointing to a therapeutic intervention strategy.

multidisciplinary sciences

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the mechanisms and treatment strategies related to brain ribosomopathies. Specifically, the research focuses on human brain ribosomopathies caused by mutations in the small nucleolar RNA (snoRNA) SNORD118. Such diseases can lead to reduced protein synthesis, increased proteotoxic stress, and p53 activation, which in turn affect the proliferation and differentiation of neural progenitor cells (NPCs) and ultimately result in symptoms such as brain developmental delay. The main objectives of the paper include:

1. **Establishing disease models**: Generate genetically engineered mice and human brain organoid models carrying SNORD118 mutations to simulate the symptoms of human brain ribosomopathies.
2. **Revealing pathological mechanisms**: Explore how SNORD118 mutations lead to ribosome biogenesis defects, reduced protein synthesis, increased proteotoxic stress, and activation of the p53 signaling pathway, which together result in reduced proliferation of NPCs.
3. **Exploring treatment strategies**: Screen small - molecule compounds to find methods that can reverse the cellular defects caused by SNORD118 mutations. In particular, the study found that the small molecule 2BAct can inhibit the integrated stress response (ISR), thereby alleviating the defects of ribosomopathies.

### Main findings

1. **Model establishment**:
- Generated genetically engineered mice and human brain organoid models with SNORD118 mutations.
- These models showed reduced protein synthesis, increased proteotoxic stress, and p53 activation, leading to reduced NPCs proliferation and increased cell death, and ultimately resulting in brain growth retardation.

2. **Pathological mechanisms**:
- SNORD118 mutations lead to reduced expression of U8 snoRNA, affecting rRNA maturation and ribosome biogenesis.
- Defects in ribosome biogenesis lead to reduced protein synthesis, triggering proteotoxic stress and activating the p53 signaling pathway.
- p53 activation further leads to cell - cycle arrest and apoptosis, reducing the number of NPCs.

3. **Treatment strategies**:
- Through screening small - molecule compounds, it was found that 2BAct can effectively inhibit the ISR and alleviate the NPCs defects caused by SNORD118 mutations.
- After 2BAct treatment, both rRNA synthesis and protein synthesis were improved, and the proliferative ability of NPCs was also restored.

### Conclusion

This study, by establishing mouse and brain organoid models with SNORD118 mutations, revealed the mechanisms by which SNORD118 mutations cause brain ribosomopathies and found that 2BAct, as a potential therapeutic drug, can effectively relieve these defects. This provides a new direction for the development of treatment strategies for ribosomopathies.